Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.

"Declarations Ethics approval and consent to participateNot applicable. Consent for publicationNot applicable. Competing interestsRJM reports research support and honoraria from Abbott, American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim/Eli Lilly and Company, Boston Scientific, Cytokinetics, Fast BioMedical, Gilead Sciences, Innolife, Medtronic, Merck, Novartis, Relypsa, Respicardia, Roche, Sanofi, Vifor, and Windtree Therapeutics and is Chair of the Council on the Kidney in Cardiovascular Disease, American Heart Association. SAB reports serving on the advisory board and speaker bureau for AstraZeneca, Boehringer Ingelheim/Eli Lilly and Company, and NovoNordisk and is on the on the advisory board for Abbott Diabetes Care. JR reports consultancy agreements with AstraZeneca, Boehringer Ingelheim/Eli Lilly and Company, and Edwards Lifesciences and serves on the medical advisory board of Procyrion Inc. (Aortix™) Competing interests RJM reports research support and honoraria from Abbott, American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim/Eli Lilly and Company, Boston Scientific, Cytokinetics, Fast BioMedical, Gilead Sciences, Innolife, Medtronic, Merck, Novartis, Relypsa, Respicardia, Roche, Sanofi, Vifor, and Windtree Therapeutics and is Chair of the Council on the Kidney in Cardiovascular Disease, American Heart Association. SAB reports serving on the advisory board and speaker bureau for AstraZeneca, Boehringer Ingelheim/Eli Lilly and Company, and NovoNordisk and is on the on the advisory board for Abbott Diabetes Care. JR reports consultancy agreements with AstraZeneca, Boehringer Ingelheim/Eli Lilly and Company, and Edwards Lifesciences and serves on the medical advisory board of Procyrion Inc. (Aortix™)"

"Funding This work was supported by Boehringer Ingelheim Pharmaceuticals Inc. and Lilly, USA LLC. The authors received no direct compensation related to the development of the manuscript."